

The amendments to page 46 of the specification are made to identify the residues of myostatin represented by SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6. These amendments are supported by page 46 of the specification and by Figure 1.

### Conclusion

Applicant respectfully submits that the claims are in condition for allowance and notification to that effect is requested. The Examiner is invited to telephone Applicant's attorney (612-373-6959) to facilitate prosecution of this application.

If necessary, please charge any additional fees or credit overpayment to Deposit Account No. 19-0743.

Respectfully submitted,

MOHAMED E. EL HALAWANI ET AL.

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.  
P.O. Box 2938  
Minneapolis, MN 55402  
(612) 373-6959

Date

October 11, 2001

By



Janet E. Emperson  
Reg. No. 39,665

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner of Patents, Washington, D.C. 20231, on this 11 day of October, 2001.

Name

Seattamattie Greg

Signature

Seattamattie Greg

FOI b7D - 92845260

**Clean Version of the First Full Paragraph of Page 46**

**USE OF PASSIVE MYOSTATIN IMMUNIZATION**

Applicant: Mohamed E. El Halawani et al.

Serial No.: 09/754,826

AI  
Myostatin peptides were prepared. The peptides were C1 (Asn-Met-Leu-Tyr-Phe-Asn-Gly-Lys-Glu-Gln-Ile-Ile-Tyr-Gly-Lys-Ile; residues 83-98; SEQ ID NO:4), D1 (Asp-Cys-Asp-Glu-His-Ser-Thr-Glu-Ser-Arg-Cys; residues 5-15; SEQ ID NO:5), and E1 (Ile-Ala-Pro-Lys-Arg-Tyr-Lys-Ala-Asn; residues 33-41; SEQ ID NO:6). Each received a peptide immunogen and the sequences were chosen based on relative hydrophilicity/hydrophobicity.

09/754,826 - 101601